Latest News

Latest News

News from the World Hepatitis Alliance

Promoting screening among high risk communities with new multi-lingual tool

31 Jan 2015 Bridie Taylor

In Europe, migrant populations are disproportionally affected by hepatitis B and C. Crucial to reducing the burden is improving screening among these...

Joining expert committees to promote harm reduction

31 Jan 2015 Bridie Taylor

Harm reduction policies are proven to save lives. Globally, as many as 67% of People Who Inject Drugs (PWIDs) have hepatitis C and an additional 8.4...

World Hepatitis Alliance’s ever-growing membership base

31 Jan 2015 Bridie Taylor

Central to the success of the World Hepatitis Alliance are our member groups around the world. To stimulate political interest in and action on...

Exploring new treatment developments and innovative ways to finance healthcare

31 Jan 2015 Bridie Taylor

New therapeutic developments are revolutionising the way hepatitis is treated. But with a global lack of funding, how can these pioneering new drugs...

Assisting WHO in the development of a global strategy

31 Jan 2015 Bridie Taylor

World Health Organization Member States have urged WHO to develop a comprehensive global strategy on hepatitis. To assist in the development of this...

Pages

News from infohep

Diabetes raises the risk of liver damage in people with HIV

21 Sep 2020 Keith Alcorn
Almost half of people with HIV with unexplained liver enzyme elevations or other abnormal liver markers had NASH and 39 of 116 had stage F3 or F4...

Models can help predict liver cancer in people cured of hepatitis C

17 Sep 2020 Liz Highleyman
Three new methods using readily available clinical parameters can help predict who will develop hepatocellular carcinoma (HCC) after achieving...

International registries provide more information about COVID-19 and liver disease

17 Sep 2020 Liz Highleyman
People with advanced liver cirrhosis are more likely to develop severe COVID-19 complications and to die from it, but those who have received liver...

Aldafermin reduces liver fat in phase 2 study

14 Sep 2020 Keith Alcorn
Aldafermin significantly reduced liver fat content and liver damage in a phase 2 study of a 24-week treatment course, Dr Stephen Harrison, Visiting...

Fatty liver disease affects one in four in Europe, study estimates

7 Sep 2020 Keith Alcorn
Non-alcoholic fatty liver disease affects one in four people in the general population in Europe and just over one in twenty people have advanced...

Stopping antivirals may offer a chance for a hepatitis B cure

6 Sep 2020 Liz Highleyman
Discontinuation of long-term nucleoside/nucleotide antiviral treatment for hepatitis B can allow some people to achieve a cure, according to a pair...

Immunotherapy combinations show promise for advanced liver cancer

2 Sep 2020 Liz Highleyman
Three checkpoint inhibitor immunotherapy regimens show promise for people with hepatocellular carcinoma (HCC), the most common type of liver cancer,...

Gilead immune modulator has modest effect on hepatitis B surface antigen

1 Sep 2020 Keith Alcorn
Selgantolimod, a toll-like receptor agonist designed to enhance immune responses to hepatitis B virus, showed only modest effects on hepatitis B...

Bulevirtide shows promise as maintenance therapy for hepatitis D

30 Aug 2020 Liz Highleyman
High-dose bulevirtide (Hepcludex) combined with pegylated interferon alfa-2a (Pegasys) or tenofovir disoproxil fumarate (TDF; Viread) led to...

JNJ-3989 achieves sustained reductions in hepatitis B surface antigen

29 Aug 2020 Keith Alcorn
Johnson & Johnson’s short interfering RNA treatment for hepatitis B resulted in sustained reductions in hepatitis B surface antigen when...